Mündliche Prüfung »   Lenvatinib mesilate

Lenvatinib mesilate, also known as Lenvima, is a small molecule inhibitor of multiple tyrosine kinases (TKIs) that has demonstrated promising efficacy in the treatment of various solid tumors. It is currently approved for the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).https://www.qingmupharm.com/products/human-apis/lenvatinib-mesilate-api